IONIS PHARMACEUTICALS INC (IONS)

80 1.34 (1.7%)

As of 2026-03-03 19:57:27 EST

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.

Traded asNasdaq: IONS
ISINUS4622221004
CIK0000874015
LEI549300SI4ZGLG0BLUZ92
EIN330336973
SectorBiotechnology
IndustryPharmaceutical Preparations
CEOBrett P. Monia
Employees1,069
Fiscal Year End1231
Address2855 GAZELLE COURT, CARLSBAD, CA, 92010
Phone7609319200
Websitehttp://ionispharma.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
IONSIONIS PHARMACEUTICALS INC2026-03-03 19:57:27801.341.7
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
IONS0000874015IONIS PHARMACEUTICALS INCUS4622221004549300SI4ZGLG0BLUZ92330336973Nasdaq2834Pharmaceutical Preparations1231CA2855 GAZELLE COURTCARLSBADCA92010UNITED STATESUS76093192002855 GAZELLE COURT, CARLSBAD, CA, 920102855 GAZELLE COURT, CARLSBAD, CA, 92010ISIS PHARMACEUTICALS INCBiotechnology1989Brett P. Monia1,069http://ionispharma.com5,738,934,243161,137,930161,974,393Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in discovering and developing antisense therapy, as well as RNA interference and CRISPR therapeutics. The company was founded in 1989 is based in Carlsbad, California. The company was previously known as Isis Pharmaceuticals until December 2015.2026-02-26 15:58:17
This is a preview of the latest data. Subscribe to access the full data.
IONS Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
IONS Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20255,275,488,712-463,445,531-8.0755165,192,0116,227,2393.9174
20245,738,934,2431,495,612,83335.2463158,964,77213,212,9759.0654
20234,243,321,410438,616,67611.5283145,751,7972,797,8041.9571
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Mariana BaroldiDirector2024240,76094,047236,915—17,101679,035
Mariana BaroldiDirector2023218,200104,17571,730—20,028513,949
Mariana BaroldiDirector2022204,98649,88347,139—18,773370,238
Richard S. GearyChief Development Officer, Executive Vice President2020509,360281,1671,502,162—78,3794,011,036
Elizabeth L. HougenChief Financial Officer, Executive Vice President2020499,555298,7341,663,208—63,8384,341,100
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20251,402
20241,069
2023927
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue943,711,000705,138,000787,647,000
Cost Of Revenue15,909,00011,215,0009,133,000
Gross Profit———
Research And Development Expenses915,619,000901,530,000899,625,000
General And Administrative Expenses393,867,000267,474,000232,619,000
Operating Expenses1,325,395,0001,180,219,0001,141,377,000
Operating Income-381,684,000-475,081,000-353,730,000
Net Income-381,387,000-453,897,000-366,286,000
Earnings Per Share Basic-2.38-3.04-2.56
Earnings Per Share Diluted-2.38-3.04-2.56
Weighted Average Shares Outstanding Basic160,010,000149,514,000143,190,000
Weighted Average Shares Outstanding Diluted160,010,000149,514,000143,190,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents372,260,000242,077,000399,266,000
Marketable Securities Current1,579,217,0001,403,466,0001,311,396,000
Accounts Receivable66,059,00092,188,00097,778,000
Inventories10,048,00012,512,00028,425,000
Non Trade Receivables———
Other Assets Current237,092,000217,934,000184,449,000
Total Assets Current2,990,635,0002,620,290,0002,641,853,000
Marketable Securities Non Current773,711,000652,542,000653,494,000
Property Plant And Equipment123,048,00094,251,00071,043,000
Other Assets Non Current171,604,000127,278,000105,280,000
Total Assets Non Current533,201,000383,385,000348,219,000
Total Assets3,523,836,0003,003,675,0002,990,072,000
Accounts Payable28,082,00042,964,00026,027,000
Deferred Revenue73,761,00078,989,000151,128,000
Short Term Debt432,120,000165,000157,000
Other Liabilities Current22,738,0009,279,0008,831,000
Total Liabilities Current781,567,000309,318,000448,090,000
Long Term Debt1,812,405,0001,253,062,0001,308,360,000
Other Liabilities Non Current———
Total Liabilities Non Current2,161,179,0001,949,502,0001,914,112,000
Total Liabilities3,034,747,0002,415,324,0002,603,386,000
Common Stock163,000158,000144,000
Retained Earnings-2,631,195,000-2,200,000,000-1,795,911,000
Accumulated Other Comprehensive Income-25,281,000-30,811,000-32,645,000
Total Shareholders Equity489,089,000600,000,000386,686,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization10,008,0009,614,00010,292,000
Share Based Compensation Expense133,874,000130,200,000105,809,000
Other Non Cash Income Expense———
Change In Accounts Receivable———
Change In Inventories13,674,0005,071,0006,392,000
Change In Non Trade Receivables———
Change In Other Assets33,212,00025,857,00029,840,000
Change In Accounts Payable-15,360,00015,990,0008,119,000
Change In Other Liabilities———
Cash From Operating Activities-268,583,000-500,947,000-307,513,000
Purchases Of Marketable Securities1,918,562,0001,852,858,0001,770,814,000
Sales Of Marketable Securities1,697,870,0001,769,172,0001,584,676,000
Acquisition Of Property Plant And Equipment51,444,00045,280,00023,805,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-277,776,000-134,027,000-214,127,000
Tax Withholding For Share Based Compensation—00
Payments Of Dividends———
Issuance Of Common Stock0489,120,000—
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities192,604,00033,609,00049,442,000
Cash From Financing Activities675,840,000478,058,000644,082,000
Change In Cash130,183,000-157,189,000122,794,000
Cash At End Of Period372,260,000242,077,000399,266,000
Income Taxes Paid-639,000-5,620,00048,334,000
Interest Paid10,782,00010,869,0006,512,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-2.38-3.04-2.56
Price To Earnings Ratio-33.2395-11.5-19.7617
Earnings Growth Rate-21.710518.7534.7368
Price Earnings To Growth Ratio1.531-0.6133-0.5689
Book Value Per Share3.05663.93512.7005
Price To Book Ratio25.88168.884218.7335
Ebitda-354,756,000-432,909,000-295,000,000
Enterprise Value14,530,656,1006,238,159,4408,153,233,100
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio4.58922.08873.3839
Capital Expenditures38,805,00032,822,0007,041,000
Free Cash Flow-307,388,000-533,769,000-314,554,000
Return On Equity-0.7798-0.7565-0.9472
One Year Beta0.72350.74910.5727
Three Year Beta0.68470.80070.8643
Five Year Beta0.81240.85060.8692
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
BENNETT C FRANKEVP, Chief Scientific Officer2026-02-27261A100,554
Birchler BrianEVP, Corp and Development Ops2026-02-27351A66,598
Monia Brett PDirector, Chief Executive Officer2026-02-27484A254,981
O'NEIL PATRICK R.EVP CLO & General Counsel2026-02-27376A72,359
Swayze EricEVP Research2026-02-27256A32,361
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Sheldon WhitehouseSenator2016-02-23Sale (Full)2016-01-20Self$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Daniel Goldman2023-04-17NY10Sale2023-03-06—$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
GROUPAMA ASSET MANAGMENT2025-12-3160,668,589766,88979.11
Alpine Global Management, LLC2025-12-314,240,29653,60079.11
Bell Investment Advisors, Inc2025-12-314,8266179.1148
Wealth Preservation Advisors, LLC2025-12-3111,86715079.1133
Sunbelt Securities, Inc.2025-12-3180,2181,01479.1105
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
PIMCO Equity Series2025-12-31PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETFMFUS71656,642.760.0269
RYDEX SERIES FUNDS2025-12-31Class CRYCFX19,6931,557,913.231.4292
RYDEX SERIES FUNDS2025-12-31Class ARYBOX19,6931,557,913.231.4292
RYDEX SERIES FUNDS2025-12-31Class HRYOAX19,6931,557,913.231.4292
RYDEX SERIES FUNDS2025-12-31Investor ClassRYOIX19,6931,557,913.231.4292
This is a preview of the latest data. Subscribe to access the full data.